Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
Status:
Completed
Trial end date:
2015-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is
not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels
by > 30% from baseline among patients with chronic kidney disease (CKD) and secondary
hyperparathyroidism (SHPT) who require management with hemodialysis.